AstriVax

📍 Heverlee, Belgium👥 30 employees💰 Last funded Jul 2022
Biotechnology Research🌐 astrivax.com
Website LinkedIn
AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is building a first in class Plug & Play vaccine platform with a patented DNA based technology that launches self-amplifying live attenuated viruses. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology by developing novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Belgium
2
Frequently asked questions
Who invested in AstriVax?
AstriVax has 2 investors on record on gritt.io.
When did AstriVax last raise funding?
The most recent investment in AstriVax recorded on gritt.io was in July 2022.
What industry is AstriVax in?
AstriVax operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is AstriVax based?
AstriVax is headquartered in Heverlee, Belgium.